We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Guardant Health (GH - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Guardant Health is a member of our Medical group, which includes 950 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Guardant Health is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for GH's full-year earnings has moved 3.7% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that GH has returned about 246.8% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 7% on a year-to-date basis. As we can see, Guardant Health is performing better than its sector in the calendar year.
Another stock in the Medical sector, Collegium Pharmaceutical (COLL - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 67%.
Over the past three months, Collegium Pharmaceutical's consensus EPS estimate for the current year has increased 9.1%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Guardant Health belongs to the Medical - Biomedical and Genetics industry, a group that includes 467 individual stocks and currently sits at #77 in the Zacks Industry Rank. On average, stocks in this group have gained 20% this year, meaning that GH is performing better in terms of year-to-date returns.
In contrast, Collegium Pharmaceutical falls under the Medical - Drugs industry. Currently, this industry has 147 stocks and is ranked #69. Since the beginning of the year, the industry has moved +7.7%.
Investors with an interest in Medical stocks should continue to track Guardant Health and Collegium Pharmaceutical. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Guardant Health (GH - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Guardant Health is a member of our Medical group, which includes 950 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Guardant Health is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for GH's full-year earnings has moved 3.7% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that GH has returned about 246.8% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 7% on a year-to-date basis. As we can see, Guardant Health is performing better than its sector in the calendar year.
Another stock in the Medical sector, Collegium Pharmaceutical (COLL - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 67%.
Over the past three months, Collegium Pharmaceutical's consensus EPS estimate for the current year has increased 9.1%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Guardant Health belongs to the Medical - Biomedical and Genetics industry, a group that includes 467 individual stocks and currently sits at #77 in the Zacks Industry Rank. On average, stocks in this group have gained 20% this year, meaning that GH is performing better in terms of year-to-date returns.
In contrast, Collegium Pharmaceutical falls under the Medical - Drugs industry. Currently, this industry has 147 stocks and is ranked #69. Since the beginning of the year, the industry has moved +7.7%.
Investors with an interest in Medical stocks should continue to track Guardant Health and Collegium Pharmaceutical. These stocks will be looking to continue their solid performance.